Women's Health

  • 3 January 2020
    Analysis

    2019 top news stories

    BMS acquires Celgene for an equity value of $74bn and GSK signs $4.2bn immunotherapy deal with the Merck group. Pharmaceutical-technology.com wraps up key headlines from 2019.

  • 13 December 2019
    News

    Amneal launches generic to NuvaRing in US

    Amneal Pharmaceuticals has launched EluRyng, a generic version of Merck’s birth control medication NuvaRing, following the US Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA).

Close
Close
Close

Go Top